On October 23, 2025, Oramed Pharmaceuticals Inc. issued a letter to shareholders announcing the termination of its joint venture with Hefei Tianhui Biotech Co. Ltd. (HTIT). The termination was triggered by HTIT’s inability to satisfy the closing financial conditions required under the joint venture agreement.
With the joint venture dissolved, Oramed will now pursue its refined oral insulin program independently. The company stated it will maintain full control over the development of ORMD‑0801 and will seek alternative manufacturing arrangements to advance the program in the United States.
The letter also highlighted Oramed’s diversified investment portfolio, noting continued appreciation in its holdings of Scilex, Alpha Tau Medical, and other assets. However, the termination of the HTIT partnership marks a significant strategic shift, as the company moves away from a joint venture model toward an in‑house development path for its core oral insulin technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.